Aliases & Classifications for Aphasia

MalaCards integrated aliases for Aphasia:

Name: Aphasia 12 53 54 6 42 43 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0060046
MeSH 43 D001037
UMLS 71 C0003537

Summaries for Aphasia

NINDS : 53 Aphasia is a neurological disorder caused by damage to the portions of the brain that are responsible for language production or processing.  It may occur suddenly or progressively, depending on the type and location of brain tissue involved.  Primary signs of the disorder include difficulty in expressing oneself when speaking, trouble understanding speech, and difficulty with reading and writing. Aphasia is not a disease, but a symptom of brain damage. Although it is primarily seen in individuals who have suffered a stroke, aphasia can also result from a brain tumor, infection, inflammation, head injury, or dementia that affect language-associated regions of the brain. It is estimated that about 1 million people in the United States today suffer from aphasia. The type and severity of language dysfunction depends on the precise location and extent of the damaged brain tissue. Generally, aphasia can be divided into four broad categories: (1) Expressive aphasia (also called Broca's aphasia) involves difficulty in conveying thoughts through speech or writing. The person knows what she/he wants to say, but cannot find the words he needs. (2) Receptive aphasia (Wernicke's aphasia) involves difficulty understanding spoken or written language. The individual hears the voice or sees the print but cannot make sense of the words. (3) Global aphasia results from severe and extensive damage to the language areas of the brain.  People lose almost all language function, both comprehension and expression. They cannot speak or understand speech, nor can they read or write.  (4) Individuals with anomic or amnesia aphasia, the least severe form of aphasia, have difficulty in using the correct names for particular objects, people, places, or events.

MalaCards based summary : Aphasia is related to epilepsy-aphasia spectrum and frontotemporal lobar degeneration with tdp43 inclusions, grn-related, and has symptoms including seizures, fever and dyspnea. An important gene associated with Aphasia is L1CAM (L1 Cell Adhesion Molecule), and among its related pathways/superpathways are Parkinson disease and Neuroscience. The drugs Levodopa and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and cellular

Disease Ontology : 12 A language disorder that involves an acquired impairment of any laguage modality such as producting or comprehending spoken or written language.

MedlinePlus : 42 Aphasia is a disorder caused by damage to the parts of the brain that control language. It can make it hard for you to read, write, and say what you mean to say. It is most common in adults who have had a stroke. Brain tumors, infections, injuries, and dementia can also cause it. The type of problem you have and how bad it is depends on which part of your brain is damaged and how much damage there is. There are four main types: Expressive aphasia - you know what you want to say, but you have trouble saying or writing what you mean Receptive aphasia - you hear the voice or see the print, but you can't make sense of the words Anomic aphasia - you have trouble using the correct word for objects, places, or events Global aphasia - you can't speak, understand speech, read, or write Some people recover from aphasia without treatment. Most, however, need language therapy as soon as possible. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 74 Aphasia is an inability to comprehend or formulate language because of damage to specific brain regions.... more...

Related Diseases for Aphasia

Diseases related to Aphasia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 480, show less)
# Related Disease Score Top Affiliating Genes
1 epilepsy-aphasia spectrum 34.8 GRIN2A CNKSR2
2 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 34.7 MAPT GRN
3 nominal aphasia 34.5 TARDBP MAPT GRN CHMP2B C9orf72 APOE
4 progressive non-fluent aphasia 34.5 TBK1 PSEN1 MAPT GRN CHMP2B C9orf72
5 gerstmann syndrome 33.7 MAPT APOE
6 semantic dementia 33.6 TARDBP PSEN1 MAPT GRN CHMP2B C9orf72
7 agraphia 32.8 TARDBP PRNP MAPT GRN C9orf72
8 frontotemporal dementia, chromosome 3-linked 32.8 TARDBP MAPT GRN CHMP2B
9 apraxia 32.8 PSEN1 MAPT GRN FOXP2 C9orf72 APOE
10 inclusion body myopathy with paget disease of bone and frontotemporal dementia 32.3 TARDBP CHMP2B C9orf72
11 frontotemporal dementia 32.0 TBK1 TARDBP SNCA PSEN1 PRNP MAPT
12 alexia 31.7 MAPT GRN APOE
13 supranuclear palsy, progressive, 1 31.7 TARDBP SNCA PSEN1 PRNP MAPT LRRK2
14 pick disease of brain 31.7 TARDBP SNCA PSEN1 PRNP OPTN MAPT
15 corticobasal degeneration 31.6 TARDBP MAPT LRRK2
16 dysgraphia 31.6 TARDBP MAPT GRN CHMP2B C9orf72
17 speech disorder 31.5 SRPX2 MAPT GRIN2A FOXP2
18 ideomotor apraxia 31.4 TARDBP MAPT GRN
19 echolalia 31.3 MAPT GRN FOXP2
20 visual agnosia 31.2 PSEN1 MAPT GRN APOE
21 pica disease 31.2 TARDBP MAPT C9orf72
22 anosognosia 31.1 C9orf72 APOE
23 amnestic disorder 31.1 PSEN1 MAPT BDNF APP APOE
24 posterior cortical atrophy 31.0 MAPT APOE
25 tremor 31.0 SNCA MAPT LRRK2
26 lateral sclerosis 30.9 TBK1 TARDBP OPTN CHMP2B C9orf72
27 prosopagnosia 30.9 TARDBP MAPT GRN
28 mutism 30.9 PRNP MAPT GRN GRIN2A GRIN1 CHMP2B
29 dyscalculia 30.9 TARDBP GRN CHMP2B
30 epilepsy 30.9 SRPX2 MAPT GRIN2A GRIN1 BDNF APP
31 creutzfeldt-jakob disease 30.8 SNCA PRNP MAPT BDNF APP APOE
32 associative agnosia 30.8 TARDBP MAPT GRN CHMP2B C9orf72
33 meningoencephalitis 30.8 PSEN1 BDNF APP
34 primary lateral sclerosis, adult, 1 30.7 SNCA MAPT
35 temporal lobe epilepsy 30.7 PRNP GRIN2A GRIN1 BDNF
36 anxiety 30.6 SNCA GRIN2A BDNF APP APOE
37 akinetic mutism 30.5 TARDBP SNCA PRNP MAPT
38 cerebral degeneration 30.4 SNCA MAPT L1CAM APP APOE
39 gait apraxia 30.4 PRNP GRN
40 simultanagnosia 30.4 MAPT APOE
41 lrrk2 parkinson disease 30.4 SNCA LRRK2
42 motor neuron disease 30.4 TBK1 TARDBP SNCA OPTN MAPT GRN
43 multiple system atrophy 1 30.4 SNCA PRNP MAPT LRRK2
44 benign epilepsy with centrotemporal spikes 30.3 SRPX2 GRIN2A GRIN1 FOXP2 BDNF
45 early-onset, autosomal dominant alzheimer disease 30.3 PSEN1 APP
46 basal ganglia calcification 30.3 PSEN1 MAPT APP
47 movement disease 30.3 TARDBP SNCA MAPT LRRK2 GRN C9orf72
48 pseudobulbar palsy 30.3 TARDBP SRPX2 C9orf72
49 ocular dominance 30.2 GRIN2A GRIN1 BDNF
50 prion disease 30.2 TARDBP SNCA PSEN1 PRNP MAPT APP
51 dystonia 30.2 LRRK2 GRN GRIN2A CHMP2B C9orf72 BDNF
52 leukoencephalopathy, hereditary diffuse, with spheroids 30.2 SNCA PRNP MAPT APP
53 vascular dementia 30.2 PSEN1 PRNP MAPT GRIN2A APP APOE
54 alzheimer disease 30.2 TARDBP SNCA PSEN1 PRNP MAPT LRRK2
55 dementia 30.2 TBK1 TARDBP SNCA PSEN1 PRNP MAPT
56 speech and communication disorders 30.2 TARDBP SRPX2 SNCA PSEN1 MAPT GRN
57 obsessive-compulsive disorder 30.1 GRIN2A C9orf72 BDNF APOE
58 hydrocephalus 30.0 PSEN1 MAPT L1CAM C9orf72 BDNF APP
59 writing disorder 30.0 TARDBP PRNP MAPT GRN CHMP2B C9orf72
60 sleep disorder 30.0 SNCA MAPT LRRK2 BDNF APOE
61 normal pressure hydrocephalus 29.9 PSEN1 MAPT C9orf72 BDNF APP APOE
62 autism 29.9 MAPT GRIN2A GRIN1 FOXP2 BDNF APP
63 amyloidosis 29.9 SNCA PSEN1 PRNP MAPT APP APOE
64 pervasive developmental disorder 29.9 SNCA GRIN2A FOXP2 BDNF APP
65 cerebral amyloid angiopathy, cst3-related 29.8 TARDBP SNCA PSEN1 PRNP MAPT APP
66 schizophrenia 29.6 SNCA MAPT GRIN2A GRIN1 FOXP2 C9orf72
67 attention deficit-hyperactivity disorder 29.6 SNCA GRIN2A GRIN1 FOXP2 BDNF
68 huntington disease 29.5 SNCA PSEN1 PRNP MAPT GRIN2A GRIN1
69 parkinson disease, late-onset 29.5 SNCA PSEN1 PRNP MAPT LRRK2 BDNF
70 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 29.4 TBK1 TARDBP SNCA PSEN1 OPTN MAPT
71 amyotrophic lateral sclerosis 1 29.4 TBK1 TARDBP SNCA PSEN1 PRNP OPTN
72 logopenic progressive aphasia 12.7
73 epilepsy, focal, with speech disorder and with or without mental retardation 12.3
74 landau-kleffner syndrome 12.3
75 progressive supranuclear palsy-progressive non-fluent aphasia syndrome 12.3
76 masa syndrome 12.3
77 intellectual disability-expressive aphasia-facial dysmorphism syndrome 12.2
78 cerebral atrophy 11.7
79 moyamoya disease 1 11.4
80 progressive multifocal leukoencephalopathy 11.4
81 marchiafava bignami disease 11.4
82 intellectual developmental disorder with short stature and behavioral abnormalities 11.2
83 autosomal dominant partial epilepsy with auditory features 11.2
84 handl syndrome 11.1
85 spastic paraplegia 16 11.1
86 x-linked charcot-marie-tooth disease 11.1
87 chmp2b-related frontotemporal dementia 11.1
88 grn-related frontotemporal lobar degeneration 11.1
89 stroke, ischemic 10.8
90 hemiplegia 10.7
91 agnosia 10.7
92 hand skill, relative 10.6
93 residual stage of open angle glaucoma 10.6 APP APOE
94 senile plaque formation 10.6 APP APOE
95 rolandic epilepsy-speech dyspraxia syndrome 10.6 SRPX2 GRIN2A
96 dyslexia 10.5
97 binswanger's disease 10.5 MAPT APP APOE
98 amyotrophic lateral sclerosis type 15 10.5 CHMP2B C9orf72
99 amyotrophic lateral sclerosis type 22 10.5 TARDBP C9orf72
100 chromosome 17q21.31 duplication syndrome 10.5 SNCA MAPT APP
101 cognitive impairment with or without cerebellar ataxia 10.5
102 cerebral amyloid angiopathy, itm2b-related, 1 10.5 PSEN1 PRNP APP
103 branchiootic syndrome 1 10.5
104 amyotrophic lateral sclerosis type 14 10.5 OPTN CHMP2B C9orf72
105 status epilepticus 10.5
106 progressive muscular atrophy 10.5 TARDBP CHMP2B C9orf72
107 specific language disorder 10.5
108 fetal alcohol spectrum disorder 10.5 L1CAM GRIN2A BDNF
109 chronic wasting disease 10.5 SNCA PRNP APP
110 amyotrophic lateral sclerosis 12 10.5 TARDBP OPTN CHMP2B
111 fetal alcohol syndrome 10.5 L1CAM GRIN2A BDNF
112 parkinson disease 10 10.5 SNCA LRRK2
113 amyotrophic lateral sclerosis 11 10.5 TARDBP OPTN CHMP2B
114 alzheimer's disease 1 10.5 APP APOE
115 kuru 10.5 SNCA PRNP APP
116 alzheimer disease 2 10.5 PSEN1 MAPT APP APOE
117 cerebral amyloid angiopathy, app-related 10.5 PSEN1 MAPT APP APOE
118 amyloidosis, hereditary, transthyretin-related 10.4 SNCA PRNP APP
119 seizure disorder 10.4
120 ischiocoxopodopatellar syndrome with or without pulmonary arterial hypertension 10.4 PSEN1 MAPT APP APOE
121 hereditary late-onset parkinson disease 10.4 SNCA LRRK2
122 parkinson disease 3, autosomal dominant 10.4 SNCA MAPT LRRK2
123 frontotemporal dementia and/or amyotrophic lateral sclerosis 3 10.4 TARDBP C9orf72
124 polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1 10.4 PSEN1 GRN APP APOE
125 encephalitis 10.4
126 neuritis 10.4 MAPT BDNF APOE
127 amyotrophic lateral sclerosis 4, juvenile 10.4 TARDBP OPTN C9orf72
128 myositis 10.4 SNCA PSEN1 MAPT APP
129 multisystem proteinopathy 10.4 TARDBP OPTN C9orf72
130 rem sleep behavior disorder 10.4 SNCA MAPT LRRK2
131 parkinson disease 1, autosomal dominant 10.4 SNCA LRRK2
132 fatal familial insomnia 10.4 SNCA PRNP MAPT APP
133 kohlschutter-tonz syndrome 10.4 PSEN1 MAPT CNKSR2 APP
134 visual epilepsy 10.4
135 primary progressive multiple sclerosis 10.4 GRN C9orf72 BDNF APOE
136 frontotemporal dementia and/or amyotrophic lateral sclerosis 4 10.4 TBK1 TARDBP
137 auditory agnosia 10.4
138 alzheimer disease 10 10.4 MAPT APOE
139 amyotrophic lateral sclerosis 10 with or without frontotemporal dementia 10.4 TARDBP OPTN CHMP2B C9orf72
140 amyotrophic lateral sclerosis type 6 10.4 TARDBP OPTN CHMP2B C9orf72
141 spinocerebellar ataxia 2 10.4 TARDBP OPTN C9orf72
142 amyotrophic lateral sclerosis 8 10.4 TARDBP OPTN CHMP2B C9orf72
143 gaucher's disease 10.4 SNCA GRN APOE
144 postencephalitic parkinson disease 10.4 TARDBP SNCA MAPT LRRK2
145 alzheimer disease 18 10.3 SNCA APP
146 cerebrovascular disease 10.3
147 encephalopathy 10.3
148 narcolepsy 10.3 PSEN1 GRIN2A BDNF APOE
149 wilson disease 10.3 PRNP APP APOE
150 age-related hearing loss 10.3 MAPT APOE
151 communicating hydrocephalus 10.3 SNCA PSEN1 MAPT APP APOE
152 scrapie 10.3 SNCA PRNP MAPT APP APOE
153 open-angle glaucoma 10.3 TBK1 OPTN BDNF APOE
154 arteriolosclerosis 10.3 TARDBP SNCA MAPT APP APOE
155 stuttering 10.3
156 inclusion body myositis 10.3 TARDBP SNCA MAPT APP APOE
157 ataxia and polyneuropathy, adult-onset 10.3
158 head injury 10.3
159 traumatic brain injury 10.3
160 dysphagia 10.3
161 specific developmental disorder 10.3 MAPT GRIN2A FOXP2 BDNF APP
162 nervous system disease 10.3 TBK1 SNCA BDNF APP APOE
163 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 10.3 TARDBP SNCA MAPT LRRK2 C9orf72
164 migraine with or without aura 1 10.3
165 ocular motor apraxia 10.3
166 perry syndrome 10.2 TARDBP SNCA MAPT GRN CHMP2B C9orf72
167 multiple sclerosis 10.2
168 yemenite deaf-blind hypopigmentation syndrome 10.2
169 focal epilepsy 10.2
170 depression 10.2
171 primary progressive apraxia of speech 10.2
172 essential tremor 10.2 SNCA MAPT LRRK2 C9orf72 BDNF
173 meningioma, radiation-induced 10.2
174 meningioma, familial 10.2
175 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.2
176 spinal meningioma 10.2
177 secretory meningioma 10.2
178 lymphoplasmacyte-rich meningioma 10.2
179 headache 10.2
180 chromosomal disease 10.2 SNCA PSEN1 MAPT BDNF APP APOE
181 machado-joseph disease 10.2 TARDBP SNCA APOE
182 amusia 10.2
183 arteriovenous malformation 10.2
184 herpes simplex 10.2
185 gerstmann-straussler disease 10.2 SNCA PSEN1 PRNP MAPT LRRK2 APP
186 coenzyme q10 deficiency, primary, 1 10.2 SNCA MAPT
187 von economo's disease 10.2 SNCA LRRK2
188 transient cerebral ischemia 10.2
189 glioblastoma multiforme 10.2
190 herpes simplex encephalitis 10.2
191 brain injury 10.2
192 myoclonus 10.2
193 rett syndrome 10.1 L1CAM GRIN1 BDNF APOE
194 peripheral nervous system disease 10.1 SNCA OPTN LRRK2 BDNF APP
195 autosomal dominant cerebellar ataxia 10.1 TARDBP SNCA MAPT LRRK2 C9orf72 APP
196 facial paralysis 10.1
197 astrocytoma 10.1
198 intracranial embolism 10.1
199 vasculitis 10.1
200 learning disability 10.1
201 meningitis 10.1
202 47,xyy 10.1
203 grn frontotemporal dementia 10.1
204 gastrointestinal stromal tumor 10.1
205 verbal auditory agnosia 10.1
206 endocarditis 10.1
207 reading disorder 10.1
208 subacute delirium 10.1
209 bipolar disorder 10.1 MAPT GRIN2A GRIN1 BDNF APP APOE
210 neuroblastoma 10.0 SNCA PSEN1 PRNP MAPT L1CAM BDNF
211 aging 10.0
212 finger agnosia 10.0
213 typhoid fever 10.0
214 ischemia 10.0
215 middle cerebral artery infarction 10.0
216 intracranial thrombosis 10.0
217 grin2a-related speech disorders and epilepsy 10.0
218 foix chavany marie syndrome 10.0
219 febrile seizures 10.0
220 central nervous system disease 10.0 TBK1 SNCA PSEN1 PRNP MAPT BDNF
221 beta-amino acids, renal transport of 10.0
222 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
223 spondylometaphyseal dysplasia, sedaghatian type 10.0
224 uruguay faciocardiomusculoskeletal syndrome 10.0
225 dysphasia, familial developmental 10.0
226 hemidystonia 10.0
227 infective endocarditis 10.0
228 specific language impairment 10.0
229 cerebral artery occlusion 10.0
230 alcohol use disorder 10.0
231 conversion disorder 10.0
232 psychotic disorder 10.0
233 kluver-bucy syndrome 10.0
234 mood disorder 10.0
235 anterior cerebral artery infarction 10.0
236 acute disseminated encephalomyelitis 10.0
237 viral encephalitis 10.0
238 polycythemia 10.0
239 glioma 10.0
240 aneurysm 10.0
241 cerebral aneurysms 10.0
242 spasticity 10.0
243 glial tumor 10.0
244 charcot-marie-tooth disease 9.9 TARDBP SNCA LRRK2 CHMP2B C9orf72 BDNF
245 alcohol dependence 9.9
246 atrial standstill 1 9.9
247 epidermoid cysts 9.9
248 hypercholesterolemia, familial, 1 9.9
249 otitis media 9.9
250 thrombophilia due to thrombin defect 9.9
251 subacute sclerosing panencephalitis 9.9
252 malaria 9.9
253 leukemia, acute lymphoblastic 9.9
254 alacrima, achalasia, and mental retardation syndrome 9.9
255 chorea, childhood-onset, with psychomotor retardation 9.9
256 exanthem 9.9
257 ptosis 9.9
258 thrombosis 9.9
259 asymptomatic neurosyphilis 9.9
260 pertussis 9.9
261 respiratory failure 9.9
262 cat-scratch disease 9.9
263 cortical blindness 9.9
264 leukemia 9.9
265 quadriplegia 9.9
266 choreatic disease 9.9
267 dilated cardiomyopathy 9.9
268 transient global amnesia 9.9
269 diarrhea 9.9
270 hepatic encephalopathy 9.9
271 personality disorder 9.9
272 cerebral palsy 9.9
273 cerebellar disease 9.9
274 demyelinating disease 9.9
275 purpura 9.9
276 articulation disorder 9.9
277 hyperglycemia 9.9
278 paraplegia 9.9
279 eating disorder 9.9
280 pulmonary embolism 9.9
281 pathologic nystagmus 9.9
282 48,xyyy 9.9
283 autoimmune encephalitis 9.9
284 elective mutism 9.9
285 limbic encephalitis 9.9
286 mast cell activation syndrome 9.9
287 neurosyphilis 9.9
288 tuberculous meningitis 9.9
289 dementia - subcortical 9.9
290 toxic encephalopathy 9.8 SNCA PSEN1 PRNP MAPT LRRK2 GRIN2A
291 spinal muscular atrophy 9.8 TARDBP SNCA MAPT C9orf72
292 disease of mental health 9.8 TARDBP SNCA PSEN1 MAPT GRN GRIN2A
293 anisocoria 9.7
294 atherosclerosis susceptibility 9.7
295 autoimmune disease 9.7
296 bladder cancer 9.7
297 colorectal cancer 9.7
298 deafness, unilateral 9.7
299 erythroleukemia, familial 9.7
300 hair whorl 9.7
301 hashimoto thyroiditis 9.7
302 klippel-trenaunay-weber syndrome 9.7
303 medulloblastoma 9.7
304 ovarian cancer 9.7
305 papillomatosis, confluent and reticulated 9.7
306 small cell cancer of the lung 9.7
307 strabismus 9.7
308 temporal arteritis 9.7
309 down syndrome 9.7
310 takayasu arteritis 9.7
311 arachnoid cysts, intracranial 9.7
312 hyperlexia 9.7
313 polycythemia vera 9.7
314 rolandic epilepsy, mental retardation, and speech dyspraxia, x-linked 9.7
315 mental retardation, x-linked, syndromic, houge type 9.7
316 mitochondrial myopathy, infantile, transient 9.7
317 kearns-sayre syndrome 9.7
318 helicobacter pylori infection 9.7
319 malignant atrophic papulosis 9.7
320 astigmatism 9.7
321 macular degeneration, age-related, 1 9.7
322 apraxia of eyelid opening 9.7
323 homocysteinemia 9.7
324 intervertebral disc disease 9.7
325 orthostatic intolerance 9.7
326 late-onset retinal degeneration 9.7
327 parkinson disease 8, autosomal dominant 9.7
328 ovarian hyperstimulation syndrome 9.7
329 myocardial infarction 2 9.7
330 granulomatosis with polyangiitis 9.7
331 aplastic anemia 9.7
332 human immunodeficiency virus type 1 9.7
333 west nile virus 9.7
334 cavitary optic disc anomalies 9.7
335 kawasaki disease 9.7
336 diabetes mellitus, ketosis-prone 9.7
337 gastric cancer 9.7
338 myelodysplastic syndrome 9.7
339 familial cold autoinflammatory syndrome 3 9.7
340 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.7
341 leukemia, acute lymphoblastic 3 9.7
342 atrial fibrillation, familial, 15 9.7
343 spastic paraplegia, intellectual disability, nystagmus, and obesity 9.7
344 angina pectoris 9.7
345 pulmonary hypertension 9.7
346 adrenal cortical carcinoma 9.7
347 angiosarcoma 9.7
348 tick-borne encephalitis 9.7
349 epidemic typhus 9.7
350 lennox-gastaut syndrome 9.7
351 focal dystonia 9.7
352 sleep apnea 9.7
353 follicular lymphoma 9.7
354 marantic endocarditis 9.7
355 autotopagnosia 9.7
356 color agnosia 9.7
357 pain agnosia 9.7
358 phonagnosia 9.7
359 tactile agnosia 9.7
360 familial hemiplegic migraine 9.7
361 atrial fibrillation 9.7
362 cardiac arrest 9.7
363 mastoiditis 9.7
364 chronic myelomonocytic leukemia 9.7
365 sensorineural hearing loss 9.7
366 cysticercosis 9.7
367 mumps 9.7
368 chronic meningitis 9.7
369 suppression amblyopia 9.7
370 amblyopia 9.7
371 bacterial infectious disease 9.7
372 common cold 9.7
373 thrombotic thrombocytopenic purpura 9.7
374 intracranial aneurysm 9.7
375 disseminated intravascular coagulation 9.7
376 cerebral arteritis 9.7
377 pulmonary edema 9.7
378 suppurative otitis media 9.7
379 lyme disease 9.7
380 nephrotic syndrome 9.7
381 hemosiderosis 9.7
382 aseptic meningitis 9.7
383 goiter 9.7
384 pulsating exophthalmos 9.7
385 pathological gambling 9.7
386 bell's palsy 9.7
387 hepatic coma 9.7
388 locked-in syndrome 9.7
389 guillain-barre syndrome 9.7
390 carotid stenosis 9.7
391 neurosarcoidosis 9.7
392 childhood disintegrative disease 9.7
393 chronic purulent otitis media 9.7
394 avoidant personality disorder 9.7
395 thrombocytopenia 9.7
396 endogenous depression 9.7
397 lymphadenitis 9.7
398 pneumothorax 9.7
399 heart septal defect 9.7
400 vascular disease 9.7
401 mononeuritis multiplex 9.7
402 atrial heart septal defect 9.7
403 encephalomalacia 9.7
404 hyperostosis 9.7
405 post-traumatic stress disorder 9.7
406 intestinal perforation 9.7
407 essential thrombocythemia 9.7
408 basilar artery insufficiency 9.7
409 arteriosclerosis 9.7
410 kernicterus 9.7
411 wernicke encephalopathy 9.7
412 protein s deficiency 9.7
413 thrombophilia 9.7
414 hereditary spastic paraplegia 9.7
415 acute interstitial pneumonia 9.7
416 anuria 9.7
417 substance abuse 9.7
418 acute kidney failure 9.7
419 grade iii astrocytoma 9.7
420 oligodendroglioma 9.7
421 germinoma 9.7
422 cerebritis 9.7
423 pancreatic adenocarcinoma 9.7
424 liver disease 9.7
425 syphilis 9.7
426 systemic scleroderma 9.7
427 cerebellar astrocytoma 9.7
428 neurotic disorder 9.7
429 schizoaffective disorder 9.7
430 kidney disease 9.7
431 aortic valve insufficiency 9.7
432 nephrolithiasis 9.7
433 acute stress disorder 9.7
434 parasagittal meningioma 9.7
435 thyroiditis 9.7
436 situs inversus 9.7
437 muscular atrophy 9.7
438 bullous pemphigoid 9.7
439 measles 9.7
440 neuromyelitis optica 9.7
441 macroglobulinemia 9.7
442 homocystinuria 9.7
443 mechanical strabismus 9.7
444 exophthalmos 9.7
445 intracranial hypertension 9.7
446 bacterial meningitis 9.7
447 congenital syphilis 9.7
448 miliary tuberculosis 9.7
449 hypoglycemia 9.7
450 bap1 tumor predisposition syndrome 9.7
451 chchd10-related disorders 9.7
452 foxp2-related speech and language disorders 9.7
453 acute erythroid leukemia 9.7
454 alien hand syndrome 9.7
455 antisynthetase syndrome 9.7
456 cluttering 9.7
457 hashimoto encephalopathy 9.7
458 intravascular papillary endothelial hyperplasia 9.7
459 neonatal stroke 9.7
460 pseudobulbar affect 9.7
461 wallerian degeneration 9.7
462 anoxia 9.7
463 cavernous malformation 9.7
464 cerebral arteriosclerosis 9.7
465 cerebral beriberi 9.7
466 dysautonomia 9.7
467 fainting 9.7
468 hypertonia 9.7
469 hypotonia 9.7
470 neuronal migration disorders 9.7
471 spinal cord injury 9.7
472 swallowing disorders 9.7
473 syncope 9.7
474 non-herpetic acute limbic encephalitis 9.7
475 rare neurodegenerative disease 9.7
476 rapidly involuting congenital hemangioma 9.7
477 rare hereditary hemochromatosis 9.7
478 argyria 9.7
479 mills syndrome 9.7
480 dementia, lewy body 9.5 TARDBP SNCA PSEN1 PRNP MAPT LRRK2

Graphical network of the top 20 diseases related to Aphasia:



Diseases related to Aphasia

Symptoms & Phenotypes for Aphasia

UMLS symptoms related to Aphasia:


seizures, fever, dyspnea, edema, tremor, cachexia, back pain, vertigo, headache, syncope, scanning speech, cyanosis, pain, chronic pain, sciatica, sore throat, icterus, signs and symptoms, signs and symptoms, digestive, other symbolic dysfunction, hot flushes, vertigo/dizziness, sleeplessness, other symptoms involving head and neck, swelling, mass, or lump in head and neck, aprosodia, aphasic, symptoms involving head and neck, other and unspecified speech disturbances, other speech disturbances, central nervous system signs and symptoms

MGI Mouse Phenotypes related to Aphasia:

45 (showing 13, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.43 APOE APP BDNF C9orf72 CNKSR2 GRIN1
2 cellular MP:0005384 10.32 APOE APP BDNF C9orf72 GRIN1 GRN
3 homeostasis/metabolism MP:0005376 10.3 APOE APP BDNF C9orf72 GRIN1 GRN
4 growth/size/body region MP:0005378 10.27 APOE APP BDNF C9orf72 GRIN1 GRN
5 mortality/aging MP:0010768 10.27 APOE APP BDNF C9orf72 CHMP2B GRIN1
6 hematopoietic system MP:0005397 10.22 APOE APP C9orf72 GRIN1 GRN LRRK2
7 integument MP:0010771 10.22 APOE APP BDNF C9orf72 GRIN2A GRN
8 nervous system MP:0003631 10.22 APOE APP BDNF C9orf72 CHMP2B GRIN1
9 immune system MP:0005387 10.21 APOE APP C9orf72 GRN LRRK2 MAPT
10 no phenotypic analysis MP:0003012 10.1 APOE APP BDNF C9orf72 GRIN1 GRN
11 reproductive system MP:0005389 9.81 APOE APP BDNF GRIN1 GRN L1CAM
12 taste/olfaction MP:0005394 9.35 APOE BDNF GRIN1 MAPT SNCA
13 vision/eye MP:0005391 9.28 APOE BDNF CHMP2B GRIN1 GRN L1CAM

Drugs & Therapeutics for Aphasia

Drugs for Aphasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 160, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levodopa Approved Phase 4 59-92-7 6047
2
Memantine Approved, Investigational Phase 4 19982-08-2 4054
3
Carbidopa Approved Phase 4 28860-95-9 34359
4
Citalopram Approved Phase 4 59729-33-8 2771
5
tannic acid Approved Phase 4 1401-55-4
6
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
7
Topiramate Approved Phase 4 97240-79-4 5284627
8
Atorvastatin Approved Phase 4 134523-00-5 60823
9
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
10
Piracetam Approved, Investigational Phase 4 7491-74-9
11
Corticosterone Experimental Phase 4 50-22-6 5753
12 Anticonvulsants Phase 4
13 Cholinergic Agents Phase 4
14 Excitatory Amino Acid Antagonists Phase 4
15 Carbidopa, levodopa drug combination Phase 4
16 Antidepressive Agents Phase 4
17 Parasympatholytics Phase 4
18 Psychotropic Drugs Phase 4
19 Muscarinic Antagonists Phase 4
20 Serotonin Uptake Inhibitors Phase 4
21 Cholinergic Antagonists Phase 4
22 Hypoglycemic Agents Phase 4
23 Adjuvants, Immunologic Phase 4
24 Botulinum Toxins Phase 4
25 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
26 Hypolipidemic Agents Phase 4
27 Lipid Regulating Agents Phase 4
28 Anticholesteremic Agents Phase 4
29 Antimetabolites Phase 4
30 abobotulinumtoxinA Phase 4
31 Botulinum Toxins, Type A Phase 4
32 Fluorodeoxyglucose F18 Phase 4
33 Anti-Inflammatory Agents Phase 4
34 Pharmaceutical Solutions Phase 4
35 Neuroprotective Agents Phase 4
36 Protective Agents Phase 4
37
Miglustat Approved Phase 3 72599-27-0 51634
38
Donepezil Approved Phase 3 120014-06-4 3152
39
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
40
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
41
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
42
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
43
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
44
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
45 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
46
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
47 Aromatic Amino Acid Decarboxylase Inhibitors Phase 2, Phase 3
48 Anti-HIV Agents Phase 3
49 Cardiac Glycosides Phase 3
50 Anti-Retroviral Agents Phase 3
51 Glycoside Hydrolase Inhibitors Phase 3
52 Cholinesterase Inhibitors Phase 3
53 Hormones Phase 3
54 Antineoplastic Agents, Hormonal Phase 3
55 Methylprednisolone Acetate Phase 3
56 Hormone Antagonists Phase 3
57 Antiemetics Phase 3
58 glucocorticoids Phase 3
59 Gastrointestinal Agents Phase 3
60
Caffeine Approved Phase 2 58-08-2 2519
61
Galantamine Approved Phase 2 357-70-0 9651
62
Dextroamphetamine Approved, Illicit Phase 2 51-64-9 5826
63
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
64
Acetylcysteine Approved, Investigational Phase 1, Phase 2 616-91-1 12035
65
Oxytocin Approved, Vet_approved Phase 2 50-56-6 53477758 439302
66
Metformin Approved Phase 2 657-24-9 14219 4091
67
Zinc Approved, Investigational Phase 2 7440-66-6 32051
68
Lithium carbonate Approved Phase 2 554-13-2
69
Bupivacaine Approved, Investigational Phase 1, Phase 2 2180-92-9, 38396-39-3 2474
70
Ketorolac Approved Phase 1, Phase 2 66635-83-4, 74103-06-3 3826
71
Naratriptan Approved, Investigational Phase 1, Phase 2 121679-13-8, 143388-64-1 4440
72
Levetiracetam Approved Phase 2 102767-28-2 441341
73
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
74
alemtuzumab Approved, Investigational Phase 2 216503-57-0
75
Busulfan Approved, Investigational Phase 2 55-98-1 2478
76
Cysteine Approved, Nutraceutical Phase 1, Phase 2 52-90-4 5862
77
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
78
Betadex Experimental Phase 1, Phase 2 7585-39-9 320761
79 Phosphodiesterase Inhibitors Phase 2
80 Histone Deacetylase Inhibitors Phase 1, Phase 2
81 Central Nervous System Stimulants Phase 2
82 adderall Phase 2
83 Catechol Phase 2
84 N-monoacetylcystine Phase 1, Phase 2
85 Respiratory System Agents Phase 1, Phase 2
86 Antidotes Phase 1, Phase 2
87 Antioxidants Phase 1, Phase 2
88 Expectorants Phase 1, Phase 2
89 Anesthetics, Local Phase 1, Phase 2
90 insulin Phase 2
91 Insulin, Globin Zinc Phase 2
92 Liver Extracts Phase 1, Phase 2
93
Bilirubin Phase 1, Phase 2 69853-43-6, 635-65-4 21252250 5280352
94 Ketorolac Tromethamine Phase 1, Phase 2
95 Serotonin 5-HT1 Receptor Agonists Phase 1, Phase 2
96 Vasoconstrictor Agents Phase 1, Phase 2
97 Serotonin Receptor Agonists Phase 1, Phase 2
98 Cyclooxygenase Inhibitors Phase 1, Phase 2
99 BB 1101 Phase 1, Phase 2
100 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
101 Immunologic Factors Phase 2
102 Antineoplastic Agents, Immunological Phase 2
103 Alkylating Agents Phase 2
104 Immunosuppressive Agents Phase 2
105 Antirheumatic Agents Phase 2
106
Serotonin Investigational, Nutraceutical Phase 1, Phase 2 50-67-9 5202
107
Leucine Investigational, Nutraceutical Phase 2 61-90-5 6106
108
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
109
Vitamin A Approved, Nutraceutical, Vet_approved Phase 1 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
110 Deoxyglucose Phase 1
111 Retinol palmitate Phase 1
112 retinol Phase 1
113 Keyhole-limpet hemocyanin Phase 1
114 Vaccines Phase 1
115 Immunoglobulins Phase 1
116 Antibodies Phase 1
117 Antibodies, Monoclonal Phase 1
118
Fentanyl Approved, Illicit, Investigational, Vet_approved 437-38-7 3345
119
Phenol Approved, Experimental 108-95-2 996
120
Mannitol Approved, Investigational 69-65-8 6251 453
121
Guaifenesin Approved, Investigational, Vet_approved 93-14-1 3516
122
Benserazide Approved, Investigational 322-35-0
123
Cefpodoxime Approved, Vet_approved 80210-62-4, 82619-04-3 6335986
124
Norepinephrine Approved 51-41-2 439260
125 Tangerine Approved
126
Hydroxocobalamin Approved 13422-51-0 15589840 11953898
127
Dextromethorphan Approved 125-71-3 5360696 5362449
128
Quinidine Approved, Investigational 56-54-2 441074
129
Tranexamic Acid Approved 1197-18-8 5526
130
Copper Approved, Investigational 7440-50-8 27099
131
Triamcinolone Approved, Vet_approved 124-94-7 31307
132
Clopidogrel Approved 113665-84-2, 120202-66-6 60606